Stockscreener 앱 받기
29.38
2.83%
-0.795
전일 마감가:
$30.17
열려 있는:
$29.5
하루 거래량:
89,358
Relative Volume:
0.13
시가총액:
$1.91B
수익:
$87.56M
순이익/손실:
$-167.47M
주가수익비율:
-12.55
EPS:
-2.34
순현금흐름:
$-148.20M
1주 성능:
-3.09%
1개월 성능:
-4.51%
6개월 성능:
-34.83%
1년 성능:
-14.38%
1일 변동 폭
$29.15
$29.79
1주일 범위
$29.15
$31.47
52주 변동 폭
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
29.38 | 1.95B | 87.56M | -167.47M | -148.20M | -2.34 |
|
ONC
Beigene Ltd Adr
|
242.25 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.96 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.45 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.16 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times
Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com
Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria
Kymera Therapeutics presents preclinical data for KT-621 - TipRanks
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus
Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan
Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com
Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus
UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st
When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga
Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus
Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus
Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus
Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK
Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech
B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com
BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Kymera advances oral drug for autoimmune diseases - Investing.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus
Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks
Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus
Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus
Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus
Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks
Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa
Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada
Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research
Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
13.67%
자본화:
|
볼륨(24시간):